Article in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Antonio Broncano-LavadoClinical Microbiology Department, IIS-Fundación Jiménez Díaz, Autonomous University of Madrid, 28040 Madrid, Spain.
John Jairo Aguilera-CorreaInstitut de Recherche en Infectiologie de Montpellier, Centre National de la Recherche Scientifique UMR 9004, Université de Montpellier, 34293 Montpellier, France.
Françoise Roquet-BanèresInstitut de Recherche en Infectiologie de Montpellier, Centre National de la Recherche Scientifique UMR 9004, Université de Montpellier, 34293 Montpellier, France.ORCID 0000-0003-2636-3734
Laurent KremerInstitut de Recherche en Infectiologie de Montpellier, Centre National de la Recherche Scientifique UMR 9004, Université de Montpellier, 34293 Montpellier, France.ORCID 0000-0002-6604-4458
Aránzazu MedieroBone and Joint Research Unit, IIS-Fundación Jiménez Díaz, Autonomous University of Madrid, 28040 Madrid, Spain.ORCID 0000-0002-5368-574X
Mateo Seoane-BlancoDepartment of Macromolecular Structure, Centro Nacional de Biotecnologia, Consejo Superior de Investigaciones Científicas, 28049 Madrid, Spain.ORCID 0000-0003-4704-3131
Mark J van RaaijDepartment of Macromolecular Structure, Centro Nacional de Biotecnologia, Consejo Superior de Investigaciones Científicas, 28049 Madrid, Spain.ORCID 0000-0002-4781-1375
Israel PagánCentro de Biotecnología y Genómica de Plantas UPM-INIA/CSIC and E.T.S. Ingeniería Agronómica, Alimentaria y de Biosistemas, Universidad Politécnica de Madrid, 28223 Madrid, Spain.ORCID 0000-0001-8876-1194
Jaime EstebanClinical Microbiology Department, IIS-Fundación Jiménez Díaz, Autonomous University of Madrid, 28040 Madrid, Spain.ORCID 0000-0002-8971-3167
Meritxell García-QuintanillaClinical Microbiology Department, IIS-Fundación Jiménez Díaz, Autonomous University of Madrid, 28040 Madrid, Spain.ORCID 0000-0003-1889-1377
Funding
CIBERINFEC-CIBER ISCIII CB21/13/00043Instituto de Salud Carlos III (Plan Estatal de I + D+i 2017-2020), and co-funded by the European Social Fund "Investing in your future" CP19/00104MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR and FEDER PID2021-125597NB-I00Ministerio de Ciencia e Innovación (Proyectos de Transición Ecológica y Digital) TED2021-130793B-I00Vaincre la Mucoviscidose RF20230503223
6 · The paper itself
Abstract
BACKGROUND/
objectives
methodsPhylogenetic analysis, electron microscopy, growth curves, biofilm assays, checkerboard, and granuloma-like medium studies were performed.
resultsP3MA inhibited the growth of clinical samples in both planktonic and biofilm states as well as in a granuloma-like model. The study of the interaction with antibiotics revealed that P3MA exhibited an antagonistic effect combined with clarithromycin, indifference with amikacin, and synergy with imipenem.
conclusionsAll these results suggest that, after genetic engineering, P3MA could be a promising candidate for phage therapy in combination with imipenem, including lung infections.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
P3MA: A Promising Mycobacteriophage Infecting · full record | OpenQuestion